How S&P 500 Giant Pfizer Is Tackling Hard-To-Treat Cancers
Pfizer said Sunday its Braftovi-tied regimen nearly doubled the length of time colon cancer patients lived without getting sicker.
Open original sourceLoading market dashboard
Pfizer said Sunday its Braftovi-tied regimen nearly doubled the length of time colon cancer patients lived without getting sicker.
Open original source